1Jaffe N. Osteosarcoma: review of the past, impact on the fu- ture. The American experience[J]. Cancer Treat Res, 2009, 152: 239-262.
2Shelekhova KV. Changes in the WHO classification of soft tissue tumors[J]. Arkh Patol, 2015, 77(1): 48-54.
3Chou A J, Gorlick R. Chemotherapy resistance in osteosar- coma: current challenges and future directions[J]. Expert Rev Anticancer Ther, 2006, 6(7): 1075-1085.
4Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate[J]. J Clin Oncol, 2005, 23(9): 2004- 2011.
5Ferrari S, Meazza C, Palmerini E, et al. Nonmetastatic os- teosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss)[J]. Tumori, 2014, 100(6): 612-619.
6Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioau- tographic, and cytogenetic studies[J]. Cancer Res, 1970, 30 (4): 1174-1184.
7Gottesman MM, Pastan I. Biochemistry of multidrug resis- tance mediated by the multidrug transporter[J]. Annu Rev Biochem, 1993, 62: 385-427.
8Baldini N, Scotlandi K, Barbanti-Br6dano G, et al. Expres- sion of P-glycoprotein in high-grade osteosarcomas in rela- tion to clinical outcome[J]. N Engl J Med, 1995, 333(21): 1380-1385.
9Loe DW, Deeley RG, Cole SR Biology of the multidrug re- sistance- associated protein, MRP[J]. Eur J Cancer, 1996, 32A(6): 945-957.
10Ming X, Thakker DR. Role of basolateral efflux transport- er MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil[J]. Biochem Pharmacol, 2010, 79(3): 455-462.
